Prostate Cancer
Amgen Protocol 20250211: A Phase 1b, Open-Label Study of Xaluritamig (AMG 509) inAdults With Metastatic Castration-Resistant Prostate Cancer
- Details
ClinicalTrials.gov ID:
NCT07493512
Diagnosis Type:
NA
USOR Number:
- Address
,
P: